Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A3 | P48764 | 18/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.46 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.42 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.42 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12362895 | 1.00 | SLC9A3 (0.49) | SLC9A3CYP2D6TRPC3TRPC7TRPC6 | |
| SCHEMBL12362897 | 0.88 | SLC6A2 (0.46) | SLC9A3CYP2D6TRPC3TRPC7TRPC6 | |
| SCHEMBL2189958 | 0.88 | SLC6A2 (0.46) | SLC9A3CYP2D6TRPC3TRPC7TRPC6 | |
| SCHEMBL2186484 | 0.79 | SLC6A2 (0.47) | SLC9A3CYP2D6TRPC3TRPC7TRPC6 | |
| SCHEMBL12362905 | 0.79 | SLC9A3 (0.42) | SLC9A3CYP2D6TRPC3TRPC7TRPC6 | |
| SCHEMBL12362909 | 0.79 | SLC6A2 (0.47) | SLC9A3CYP2D6TRPC3TRPC7TRPC6 | |
| SCHEMBL2190063 | 0.79 | SLC9A3 (0.42) | SLC9A3CYP2D6TRPC3TRPC7TRPC6 | |
| SCHEMBL12363276 | 0.79 | TRPC6 (0.67) | SLC9A3CYP2D6TRPC3TRPC7TRPC6 | |
| SCHEMBL2187767 | 0.78 | SLC9A3 (0.43) | SLC9A3CYP2D6TRPC3TRPC7TRPC6 | |
| SCHEMBL12362906 | 0.78 | SLC9A3 (0.43) | SLC9A3CYP2D6TRPC3TRPC7TRPC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342178-B1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI SA (FR) | 2016-09-28 | — | — | EP | claimed |
| US-8822449-B2 | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | SANOFI (FR) | 2014-09-02 | — | — | US | claimed |
| US-20110201590-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI-AVENTIS (FR) | 2011-08-18 | — | — | US | claimed |
| EP-2342178-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | Sanofi-Aventis (FR) | 2011-07-13 | — | — | EP | claimed |
| WO-2010025856-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI-AVENTIS (FR) | 2010-03-11 | — | — | WO | claimed |
| EP-2342178-B1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI SA (FR) | 2016-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201590-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | CFTR, AADAT, PKD1 | SLC9A3 750/4885CYP2D6 127/4885TRPC3 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.